Might take a few weeks for the fresh allocation to balance ......

First 26 Last

Share
Profile

Follow
Akki

35,692 Posts.

552

05/08/20

13:14

Post #: 46318577
Share

Originally posted by Akki ↑

That was a good juicy update ... wedge will break soon - it loves that high....

Still probably more likely on base once stock is allocated

but who knows tricky position, wedge says sooner and too late once allocated.

Patrys’ lead asset PAT-DX1 exploits the DNA Damage Response (DDR) mechanism to block DNA repair and preferentially kill cancer cells. In animal models, PAT-DX1 has shown efficacy in killing cancer cells with a range of DDR gene mutations such as BRCA2 and PTEN – and importantly it does not kill cells without those mutations (i.e. healthy cells). This could be a game changer in the oncology space. PAT-DX1 is the only known antibody to have shown efficacy as a single agent via the synthetic lethality model. Unlike other antibodies and 98% of small molecules, it can also cross the blood brain barrier (BBB), which provides all-important access to cancer cells in the central nervous system.

Synthetic lethality has also attracted a lot of deal making attention in the past few weeks. In May 2020, Bristol Myers Squibb closed a US$65M deal with Repare Therapeutics for access to its DDR technology platform, and Glaxo Smith Kline inked a deal with IDEAYA Biosciences for three discovery-stage synthetic lethality assets (US$100M upfront, US$20M equity investment, potential development and regulatory milestone payments of around US$465-485M and commercial milestones of US$475M for two of the more advanced programs). It is clear that big pharma and big biotech are increasingly compelled by the elegance of synthetic lethality and DDR therapeutic approaches for treating a range of tumours.

Patrys is in the enviable position of developing a novel therapeutic that combines the established safety and toxicology advantages of antibody therapeutics with the power of synthetic lethality – and it is designed to ‘topple’ the most stubborn, hard-to-reach cancers.

Expand

Might take a few weeks for the fresh allocation to balance ... but it's up from there.

Would be surprised if there wasn't some juicy news towards end of 3Q or early next.

PAB Price at posting: 1.3¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 13 more messages in this thread...

First 26 Last

Add PAB (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $14.40M

Open	High	Low	Value	Volume
0.6¢	0.7¢	0.6¢	$589	91.50K

Buyers (Bids)

No.	Vol.	Price($)
24	4759154	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	1636778	2

View Market Depth

No.	Vol.	Price($)
24	4759154	0.006
13	6829276	0.005
7	4425000	0.004
4	2729016	0.003
2	4520000	0.002

Price($)	Vol.	No.
0.007	1636778	2
0.008	4991280	4
0.010	1592000	4
0.011	1080000	2
0.012	552407	4

Last trade - 16.10pm 09/07/2024 (20 minute delay)

PAB (ASX) Chart

Might take a few weeks for the fresh allocation to balance ......

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Might take a few weeks for the fresh allocation to balance ......

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News